Get started
Author

Gianluca Del Conte

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
2023 · Kim N. Chi, Dana Rathkopf, et al. · Journal of Clinical Oncology · 381
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
2008 · Cristiana Sessa, Aymeric Guibal, et al. · Nature Clinical Practice Oncology · 152
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
2014 · G Del Conte, C Sessa, et al. · British Journal of Cancer · 104
PDF
A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer
2017 · Zev A. Wainberg, Maria Alsina, et al. · Targeted Oncology · 103
PDF
A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer
2012 · S.B. Kaye, C.J. Poole, et al. · Annals of Oncology · 93
PDF
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
2016 · J. E. Grilley-Olson, P. L. Bedard, et al. · Investigational New Drugs · 84
Patient Selection for Oncology Phase I Trials: A Multi-Institutional Study of Prognostic Factors
2012 · David Olmos, Roger P. A'Hern, et al. · Journal of Clinical Oncology · 81
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers
2013 · Giampaolo Bianchini, Lajos Pusztai, et al. · Breast Cancer Research · 57
PDF
162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
2022 · E.P. Hamilton, C.L. Shapiro, et al. · Annals of Oncology · 36
Clinical Development Strategies and Outcomes in First-in-Human Trials of Monoclonal Antibodies
2015 · Diego Tosi, Yassine Laghzali, et al. · Journal of Clinical Oncology · 36
PDF
Single-Agent Divarasib in Patients With KRAS G12C –Positive Non–Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study
2025 · Adrian G. Sacher, Wilson H. Miller, et al. · Journal of Clinical Oncology · 35
Phase I clinical and pharmacokinetic study of ombrabulin (AVE8062) combined with cisplatin/docetaxel or carboplatin/paclitaxel in patients with advanced solid tumors
2014 · Rastislav Bahleda, Cristiana Sessa, et al. · Investigational New Drugs · 27
An Open-Label Phase 2 Study of Twice-Weekly Bortezomib and Intermittent Pegylated Liposomal Doxorubicin in Patients With Ovarian Cancer Failing Platinum-Containing Regimens
2012 · Gabriella Parma, Rosanna Mancari, et al. · International Journal of Gynecological Cancer · 21
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors
2013 · Cristiana Sessa, Gianluca Del Conte, et al. · Investigational New Drugs · 15
Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
2025 · Pascale Tomasini, Yongsheng Wang, et al. · Journal of Clinical Oncology · 13
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors (NCT01193595).
2012 · Gianluca Del Conte, Rastilav Bahleda, et al. · Journal of Clinical Oncology · 10
Symptomatologic outcomes of gut microbiota modifiers (probiotics, prebiotics and synbiotics) in cancer care: A scoping review of randomized controlled trials
2025 · Silvia Belloni, Cristina Arrigoni, et al. · Critical Reviews in Oncology/Hematology · 9
Results from a phase 1/2 study of volociximab in combination with liposomal doxorubicin in relapsed advanced epithelial ovarian and primary peritoneal carcinoma
2008 · A. Delmonte, G. Del Conte, et al. · Journal of Clinical Oncology · 9
A phase I trial of antifibronecitin 131I-L19-small immunoprotein (L19-SIP) in solid tumors and lymphoproliferative disease
2008 · G. Del Conte, D. Tosi, et al. · Journal of Clinical Oncology · 5
Factors Associated with Immune Effector Cell-Associated Neurotoxicity Syndrome in Adults with Hematological Malignancies Undergoing Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review
2025 · Silvia Belloni, Chiara Giacon, et al. · Seminars in Oncology Nursing · 4
Abstract CT022: Divarasib plus migoprotafib combination treatment in patients with KRAS G12C-positive non-small cell lung cancer (NSCLC)
2025 · Jia Luo, Adrian Sacher, et al. · Cancer Research · 4
Vinflunine (VFL) in patients (pts) with metastatic transitional cell carcinoma of the urothelial tract (mTCCU): Clinical outcome and prognostic factors in a nationwide, real-life setting (MOVIE trial).
2016 · Rodolfo Passalacqua, Silvia Lazzarelli, et al. · Journal of Clinical Oncology · 4
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.
2013 · Michael Ong, Gianluca Del Conte, et al. · Journal of Clinical Oncology · 3
Radioimmunotherapy (RIT) with 131l-L19SIP in solid cancers (SC) and lymphoproliferative diseases: Final results of the first human trial.
2010 · G. Del Conte, P. A. Erba, et al. · Journal of Clinical Oncology · 3
Tailored treatment for ovarian cancer: are we there yet?
2010 · Cristiana Sessa, Gianluca Del Conte · Nature Reviews Clinical Oncology · 3
Works count: 44
Citation count: 1,300
H-index: 14
I10-index: 16
Year
Topic
Type